Indications
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Composition
- Active substance
- lacosamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vimpat
- Active substance
- lacosamide
- ATC code
- N03AX18
- Group
- Nervous system
- Therapeutic area
- Epilepsy
- Marketing authorisation holder
- UCB Pharma SA
- Status
- Authorised
- EU authorisation
- 29 Aug 2008